Patents Assigned to Valneva
-
Patent number: 9701945Abstract: The present invention relates to the development and manufacturing of viral vaccines. In particular, the invention relates to the field of industrial production of viral vectors and vaccines, more in particular to the use of avian embryonic stem cells, preferably the EBx® cell line derived from chicken embryonic stem cells, for the production of viral vectors and viruses. The invention is particularly useful for the industrial production of viral vaccines to prevent viral infection of humans and animals.Type: GrantFiled: May 21, 2015Date of Patent: July 11, 2017Assignee: ValnevaInventors: Majid Mehtali, Patrick Champion-Arnaud, Arnaud Leon
-
Publication number: 20170107263Abstract: The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.Type: ApplicationFiled: September 16, 2016Publication date: April 20, 2017Applicant: Valneva Austria GmbHInventors: Pär Comstedt, Markus Hanner, Urban Lundberg, Andreas Meinke, Wolfgang Schüler, Benjamin Wizel
-
Publication number: 20170101446Abstract: The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.Type: ApplicationFiled: September 22, 2016Publication date: April 13, 2017Applicant: Valneva Austria GmbHInventors: Pär Comstedt, Urban Lundberg, Andreas Meinke, Markus Hanner, Wolfgang Schüler, Benjamin Wizel, Christoph Reinisch, Brigitte Grohmann, Robert Schlegl
-
Patent number: 9598472Abstract: This present invention provides C-TAB.G5 and C-TAB.G5.1 isolated polypeptides comprising the receptor binding domains of C. difficile toxin A and toxin B as set forth in the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 4. The C-TAB.G5 and C-TAB.G5.1 isolated polypeptides may be used to neutralize toxic effects of C. difficile toxin A and/or toxin B.Type: GrantFiled: September 5, 2011Date of Patent: March 21, 2017Assignees: Valneva Austria GmbH, Intercell USA, Inc.Inventors: Larry R. Ellingsworth, David Flyer, Jing-Hui Tian, Steven R. Fuhrmann, Stefanie Kluepfel-Stahl, Gregory M. Glenn, Kerstin Westritschnig
-
Publication number: 20160362480Abstract: The present invention relates to a novel trimeric OprF/I fusion protein comprising a portion of the Pseudomonas aeruginosa outer membrane protein F which is fused with its carboxy terminal end to a portion of the amino terminal end of the Pseudomonas aeruginosa out membrane protein I, wherein said portion of the Pseudomonas aeruginosa outer membrane protein F comprises the amino acids 190-342 of SEQ ID NO: 1 and wherein said portion of the Pseudomonas aeruginosa outer membrane protein I comprises the amino acids 21-83 of SEQ ID NO: 2, and further to a novel Opr F/I fusion protein which contains a disulphide bond pattern, preferably selected from the group consisting of (a) Cys18-Cys27-bond, (b) Cys18-Cys27-bond and Cys33-Cys47-bond, and (c) Cys18-Cys47 and Cys27-Cys33-bond, and to immunogenic variants thereof having at least 85% identity to the amino acid sequence of SEQ ID NO: 3.Type: ApplicationFiled: May 16, 2016Publication date: December 15, 2016Applicant: Valneva Austria GmbHInventor: ROBERT SCHLEGL
-
Publication number: 20160333056Abstract: The present invention relates to compositions and methods for the prevention and treatment of Borrelia infection. Particularly, the present invention relates to a polypeptide comprising a hybrid C-terminal fragment of an outer surface protein A (OspA), a nucleic acid coding the same, an antibody specifically binding the same, a pharmaceutical composition (particularly for use as a medicament or in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid and/or the antibody, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.Type: ApplicationFiled: January 9, 2015Publication date: November 17, 2016Applicant: Valneva Austria GmbHInventors: Urban Lundberg, Wolfgang Schüler
-
Patent number: 9492537Abstract: Described is an immunostimulatory oligodeoxynucleic acid molecule (ODN) having the structure according to formula (I), wherein any NMP is a 2? deoxynucleoside monophosphate or monothiophosphate, selected from the group consisting of deoxyadenosine-, deoxyguanosine-, deoxyinosine-, deoxycytosine-, deoxyuridine-, deoxythymidine-, 2-methyl-deoxyinosine-, 5-methyl-deoxycytosine-, deoxypseudouridine-, deoxyribosepurine-, 2-amino-deoxyribosepurine-, -6-S-deoxyguanine-, 2-dimethyl-deoxyguanosine- or N-isopentenyl-deoxyadenosine-monophosphate or -monothiophosphate, NUC is a 2? deoxynucleoside, selected from the group consisting of deoxyadenosine-, deoxyguanosine-, deoxyinosine-, deoxycytosine-, deoxyuridine-, deoxythymidine-, 2-methyl-deoxyinosine-, 5-methyl-deoxycytosine-, deoxypseudouridine-, deoxyribosepurine-, 2-amino-deoxyribosepurine-, 6-S-deoxyguanine-, 2-dimethyl-deoxyguanosine- or N-isopentenyl-deoxyadenosine, any X is O or S, a and b are integers from 0 to 100 with the proviso that a+b is between 4 and 150,Type: GrantFiled: December 30, 2014Date of Patent: November 15, 2016Assignee: Valneva Austria GmbHInventors: Walter Schmidt, Karen Lingnau, Carola Wenander, Alena Egyed
-
Patent number: 9494575Abstract: Provided are a method and means permitting the simultaneous measurement of the reactive properties of more than 10,000 of antigen-stimulated lymphocytes being held on a chip. A microwell array comprises multiple wells capturing single cells and a coating layer on a principal surface around the wells containing a substance capable of binding to a substance produced by the cells in the wells. A method for screening a target cell comprises: causing specimen cells and a cell culture broth to be contained in the wells of the microwell array; culturing the cells in a state permitting the diffusion of substances from the wells into the coating layer; feeding a label substance binding specifically to a substance produced by a target cell onto the coating layer; and detecting the substance produced by the target cell by the label substance binding around the well to specify the target cell.Type: GrantFiled: August 1, 2008Date of Patent: November 15, 2016Assignees: TOYAMA PREFECTURE, VALNEVAInventors: Aishun Jin, Hiroyuki Kishi, Atsushi Muraguchi, Tsutomu Obata
-
Publication number: 20160324959Abstract: The invention relates to means and methods for preparing aqueous composition comprising aluminium and a protein said composition comprising less than 700 ppm heavy metal on the basis of weight with respect to the aluminium content. The invention further relates to aqueous compositions comprising a protein and an aluminium-salt, said composition comprising less than 350 ppb heavy metal based on the weight of the aqueous composition.Type: ApplicationFiled: July 29, 2016Publication date: November 10, 2016Applicant: Valneva Austria GmbHInventors: ROBERT SCHLEGL, Michael Möhlen, Jürgen Wruss, Michael Weber
-
Publication number: 20160257940Abstract: The present invention relates to the development and manufacturing of viral vaccines. In particular, the invention relates to the field of industrial production of viral vectors and vaccines, more in particular to the use of avian embryonic stem cells, preferably the EBx® cell line derived from duck embryonic stem cells, for the production of viral vectors and viruses. The invention is particularly useful for the industrial production of viral vaccines to prevent viral infection of humans and animals.Type: ApplicationFiled: February 2, 2016Publication date: September 8, 2016Applicant: ValnevaInventors: Fabienne Guehenneux, Karine Moreau, Magali Esnault
-
Patent number: 9382513Abstract: The present invention relates to a method for producing avian cell lines, comprising gradual or complete withdrawal of growth factors, serum and/or feeder layer so that the established lines are adherent or nonadherent cells capable of proliferating indefinitely in a basic culture medium. The invention also relates to the cells derived from such lines which are particularly useful for the production of substances of interest.Type: GrantFiled: March 3, 2010Date of Patent: July 5, 2016Assignee: ValnevaInventors: Bertrand Pain, Fabienne Guehenneux
-
Patent number: 9359412Abstract: The present invention relates to a novel trimeric OprF/I fusion protein comprising a portion of the Pseudomonas aeruginosa outer membrane protein F which is fused with its carboxy terminal end to a portion of the amino terminal end of the Pseudomonas aeruginosa out membrane protein I, wherein said portion of the Pseudomonas aeruginosa outer membrane protein F comprises the amino acids 190-342 of SEQ ID NO: 1 and wherein said portion of the Pseudomonas aeruginosa outer membrane protein I comprises the amino acids 21-83 of SEQ ID NO: 2, and further to a novel Opr F/I fusion protein which contains a disulphide bond pattern, preferably selected from the group consisting of (a) Cys18-Cys27-bond, (b) Cys18-Cys27-bond and Cys33-Cys47-bond, and (c) Cys18-Cys47 and Cys27-Cys33-bond, and to immunogenic variants thereof having at least 85% identity to the amino acid sequence of SEQ ID NO: 3.Type: GrantFiled: March 19, 2012Date of Patent: June 7, 2016Assignee: Valneva Austria GmbHInventor: Robert Schlegl
-
Publication number: 20160114033Abstract: The invention relates to means and methods for preparing aqueous composition comprising aluminium and a protein said composition comprising less than 700 ppm heavy metal on the basis of weight with respect to the aluminium content. The invention further relates to aqueous compositions comprising a protein and an aluminium-salt, said composition comprising less than 350 ppb heavy metal based on the weight of the aqueous composition.Type: ApplicationFiled: October 2, 2015Publication date: April 28, 2016Applicant: Valneva Austria GmbHInventors: Robert Schlegl, Michael Möhlen, Jürgen Wruss, Michael Weber
-
Patent number: 9310362Abstract: A microwell array chip made of silicon and having multiple microwells where each microwell is used to store a single specimen organic cell. The microwell of the array chip is of a size and shape to hold just one organic cell and the interior surface of the microwells are coated with a fluorocarbon film.Type: GrantFiled: April 18, 2011Date of Patent: April 12, 2016Assignee: VALNEVAInventors: Atsushi Muraguchi, Hiroyuki Kishi, Yoshiharu Tokimitsu, Sachiko Kondo, Tsutomu Obata, Satoshi Fujiki, Yoshiyuki Yokoyama, Hirofumi Nabesawa, Sotohiro Takabayashi, Katsumi Tanino
-
Patent number: 9260694Abstract: The present invention relates to the development and manufacturing of viral vaccines. In particular, the invention relates to the field of industrial production of viral vectors and vaccines, more in particular to the use of avian embryonic stem cells, preferably the EBx® cell line derived from duck embryonic stem cells, for the production of viral vectors and viruses. The invention is particularly useful for the industrial production of viral vaccines to prevent viral infection of humans and animals.Type: GrantFiled: November 1, 2013Date of Patent: February 16, 2016Assignee: ValnevaInventors: Fabienne Guehenneux, Karine Moreau, Magali Esnault, Majid Mehtali
-
Patent number: 9248180Abstract: The invention discloses pharmaceutical compositions in liquid form comprising a peptide with the amino acid sequence KLKL5KLK and an oligodeoxynucleotide with the nucleic acid sequence (dIdC)13 and wherein the peptide and the oligodeoxynucleotide are present as sterile-filterable nanoparticles in the composition, thereby forming a suspension, characterized in that the mean particle size of the solid particles is less than 1 ?m.Type: GrantFiled: April 22, 2014Date of Patent: February 2, 2016Assignee: Valneva Austria GmbHInventors: Benjamin Wizel, Karin Riedl, Karen Lingnau, Ursula Schlosser, Jürgen Wruss, Robert Schlegl, Michael Weber, Christoph Reinisch, Ljubomir Paucz, Christoph Klade, Jee Loon Look, Christian Ruiz, Robert Seid
-
Patent number: 9182408Abstract: The present invention relates to a screening technology that allows the isolation of peptides able to bind to target protein, the binding of which being sensitive to the protein conformation. The invention further provides a method to identify compounds that specifically and precisely modify the protein conformation and its biological activity. Finally, the invention relates to certain peptides obtained by the method of screening of the present invention and their use as therapeutic agent for the prevention or treatment of diseases.Type: GrantFiled: September 16, 2005Date of Patent: November 10, 2015Assignee: VALNEVAInventor: Majid Mehtali
-
Publication number: 20150250865Abstract: The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.Type: ApplicationFiled: February 17, 2015Publication date: September 10, 2015Applicant: Valneva Austria GmbHInventors: Pär Comstedt, Markus Hanner, Urban Lundberg, Andreas Meinke, Wolfgang Schüler, Benjamin Wizel
-
Publication number: 20150225695Abstract: The present invention concerns a method of culturing embryonic stem (ES) cells of avian, comprising the steps of: a) suspending ES cells originating from the blastoderm disk of fertilized un-incubated avian egg(s) in a basal culture medium supplemented with: insulin-like growth factor-1 (IGF-1) and ciliary neurotrophic factor (CNTF); and animal serum; and optionally, at least one growth factors selected in the group comprising interleukin 6 (II-6), interleukin 6 receptor (II-6R), stem cell factor (SCF), fibroblast growth factor (FGF), leukaemia inhibitory factor (LIF), interleukin 11 (II-11), oncostatin and cardiotrophin; b) seeding the suspension of ES cells obtained in step a) on a layer of feeder cells and further culturing the ES cells for at least between 2 to 10 passages; c) optionally removing at least one growth factors selected SCF, FGF, II-6, II-6R, LIF, oncostatin and cardiotrophin and II-11 from the culture medium; d) further culturing the ES cells in the medium of step c) on a layer of feeder celType: ApplicationFiled: December 30, 2014Publication date: August 13, 2015Applicant: VALNEVAInventors: ISABELLE VALARCHE, LUC BATARD, MAJID MEHTALI, FABIENNE GUEHENNEUX
-
Publication number: 20150216967Abstract: The invention discloses pharmaceutical compositions in liquid form comprising a peptide with the amino acid sequence KLKL5KLK and an oligodeoxynucleotide with the nucleic acid sequence (dIdC)13 and wherein the peptide and the oligodeoxynucleotide are present as sterile-filterable nanoparticles in the composition, thereby forming a suspension, characterized in that the mean particle size of the solid particles is less than 1 ?m.Type: ApplicationFiled: April 22, 2014Publication date: August 6, 2015Applicant: Valneva Austria GmbHInventors: Benjamin Wizel, Karin Riedl, Karen Lingnau, Ursula Schlosser, Jürgen Wruss, Robert Schlegl, Michael Weber, Christoph Reinisch, Ljubomir Paucz, Christoph Klade, Jee Loon Look, Christian Ruiz, Robert Seid